Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) will report its Q4 results on Jan 31, 2018.
Vertex (VRTX) Stock Up 70% in a Year's Time: Here's Why
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) stock rallies on consistent expansion in patient population through label expansions of Kalydeco and Orkambi and positive data readout from pivotal studies.
Celgene (CELG) Q4 Preview: Will It Beat on Earnings Again?
by Zacks Equity Research
Celgene has an excellent track record and we expect the company to keep the momentum in the fourth quarter. Investors will also focus on updates on recent acqusitions.
What's in the Cards for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Novartis has an excellent track record. We expect investors to focus on the performance of new drugs and revival of Alcon business.
Amgen Gets FDA Nod to Add ENDEAVOR Data on Kyprolis Label
by Zacks Equity Research
Amgen (AMGN) gets an earlier-than-expected approval to include ENDEAVOR study OS data on Kyprolis label.
3 Top-Ranked Drug Stocks that are Broker Favorites
by Arpita Dutt
With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.
BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day
Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News
by Arpita Dutt
Is Celgene (CELG) in talks with Juno regarding a possible acquisition deal? This was the main news in the biotech sector this week.
3 Biotech Stocks Start Healthy in '18: Will the Rally Last?
by Zacks Equity Research
We take a look at some biotech stocks that have witnessed an increase in their share price this year so far and look well positioned for the rest of 2018.
Concert Pharmaceuticals Plunges on Patent Petition Setback
by Zacks Equity Research
Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
Can Biotech Keep Last Year's Momentum Alive in 2018?
by Zacks Equity Research
The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.
Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU
by Zacks Equity Research
Vertex (VRTX) receives extension of the marketing application for Orkambi to include use in children with CF who have two copies of the F508del mutation from European Commission.
Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus
by Arpita Dutt
Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.
Galapagos Reports Topline Data From Osteoarthritis Study
by Zacks Equity Research
Galapagos' (GLPG) osteoarthritis candidate, GLPG1972, reduces level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in an early stage study.
Will These 2 Large-Cap Biotechs Be on Investor Radar in '18?
by Zacks Equity Research
Both Vertex and Alexion enjoy dominant positions in medical areas - cystic fibrosis (CF) for Vertex and ultra-rare disorders for Alexion - that are not very competitive.
Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo
by Arpita Dutt
A couple of acquisition agreements as well as pipeline news from Celgene (CELG) and Biogen were the key highlights this week in the biotech sector.
Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy
by Arpita Dutt
A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.
5 Hot Stocks Driving the Nasdaq ETF Rally
by Sweta Killa
Inside the top performing stocks of the Nasdaq ETF.
Proteostasis Stock Surges on Positive Data From CF Studies
by Zacks Equity Research
Proteostasis (PTI) stock skyrockets on positive results from early and mid-stage studies on its cystic fibrosis pipeline candidates.
Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs
by Arpita Dutt
The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.
Vertex Kalydeco Study Successful in Children Aged 1-2 Years
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) phase III study evaluating Kalydeco in children as young as one year meets its primary safety endpoint.
New Pharma ETF PILL : What Investors Need to Know
by Sanghamitra Saha
Inside the pros and cons of the pharma sector and chances of outperformance of the just-launched fund PILL.
The Zacks Analyst Blog Highlights: Starbucks, NIKE, Manulife, Intuit and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Starbucks, NIKE, Manulife, Intuit and Vertex
Top Analyst Reports for Starbucks, NIKE & Manulife
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Starbucks (SBUX), NIKE (NKE) and Manulife (MFC).